Genentech Reports Positive Phase III Interim for Sefaxersen in IgAN
Genentech said Phase III IMAgINATION met its primary endpoint, with sefaxersen significantly reducing proteinuria vs placebo at 37 weeks in IgA nephropathy. Safety was consistent with prior data; the blinded study continues to week 105 for eGFR.Material DetailsContext by AI AnalystThis is a mid-to…